Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female of ages 18 to 45 inclusive~2. Body weight \> 50 kg (110 lb.) and body mass index between 18 and 28 kg/m2 inclusive~3. Medically healthy with clinically insignificant findings based on medical history, 12-lead ECG, and physical examination~4. Negative urine pregnancy test in women of childbearing potential~Exclusion Criteria:~1. Previous exposure to pegfilgrastim or filgrastim~2. Current or previous cancer, diabetes, or any clinically significant cardiovascular, metabolic, endocrine, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological, neurological, gynecologic, psychiatric, or other disorder~3. History of chronic or acute respiratory illness within the past 3 months~4. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or recreational drugs for the duration of study participation~5. No prescription or nonprescription drugs during the study~6. Participation in an investigational clinical study within 30 days prior to screening~7. History of known clinically significant drug and/or food allergies, including allergic reaction to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sequence A (Type: EXPERIMENTAL): 3 doses of CHS-1701 or Neulasta, random order
- Sequence B (Type: EXPERIMENTAL): 3 doses of CHS-1701 or Neulasta, random order
- Sequence C (Type: EXPERIMENTAL): 3 doses of CHS-1701 or Neulasta, random order

Based on this trial design, predict the completion outcome and termination type (if applicable).